BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.26.0//EN
X-ORIGINAL-URL:https://steven-kantor.com/
X-WR-CALNAME:Steven A Kantor
X-WR-CALDESC:
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-23fa71cc32babb7b91130824466d25a5@steven-kantor.com
DTSTART;TZID=America/New_York:20260820T080000
DTEND;TZID=America/New_York:20260820T180000
DTSTAMP:20260820T192114Z
CREATED:20260820
LAST-MODIFIED:20260820
PRIORITY:5
SEQUENCE:2
TRANSP:OPAQUE
SUMMARY:Jinfeng Tang: Bringing Finance, Investment, and Life Sciences Innovation Together at TangGene
DESCRIPTION:Building a successful biotechnology company requires more than breakthrough science. It also requires access to capital, strong operational leadership, strategic decision-making, and a clear understanding of how to build an emerging company.\nJinfeng Tang, Co-Founder and CEO of TangGene, brings those disciplines together through more than 20 years of experience spanning finance, risk management, startup investing, and early-stage company development.\nAdvancing Immunotherapies for Autoimmune Diseases\nAt TangGene, Jinfeng leads the company’s strategy, fundraising, and operations as the biotechnology company works to advance first-in-class immunotherapies for autoimmune diseases.\nDeveloping innovative therapies requires companies to navigate complex challenges well beyond the laboratory—from securing investment and building the right leadership team to developing an organization capable of moving promising science forward.\nJinfeng’s background provides him with a particularly interesting perspective on that journey.\nFrom Global Finance to Life Sciences Entrepreneurship\nBefore becoming an entrepreneur and investor, Jinfeng held senior positions at JPMorgan Chase, BlackRock, and Deutsche Bank, developing extensive experience in finance and risk management.\nToday, he also serves as Managing Partner of Tang Capital, where he has invested in more than a dozen technology startups, including multiple life sciences companies.\nThroughout his career, Jinfeng has worked closely with early-stage businesses in several capacities—as an investor, advisor, board member, and operating executive. That combination gives him insight into both sides of the table: what founders need to build companies and what investors look for when deciding where to commit capital.\nBuilding the Next Generation of Life Sciences Companies\nThe intersection of biotechnology, entrepreneurship, and investment is becoming increasingly important as emerging life sciences companies work to translate innovative research into viable therapies and sustainable businesses.\nLeaders such as Jinfeng demonstrate the value of combining scientific innovation with disciplined company building, financial strategy, and investment experience.\nWe look forward to hearing more about Jinfeng’s experience, the development of TangGene, and his perspective on building and financing emerging companies in today’s evolving life sciences and biotechnology ecosystem.\n
URL:https://steven-kantor.com/events/jinfeng-tang-bringing-finance-investment-and-life-sciences-innovation-together-at-tanggene/
CATEGORIES:LSC - New Jersey
ATTACH;FMTTYPE=image/jpeg:https://steven-kantor.com/wp-content/uploads/2026/08/IMG_0002-scaled-e1787268059781.jpeg
END:VEVENT
END:VCALENDAR